A pharmaceutical company is investing more than £15 million into the design and build of a new 50,000 sq ft facility in Nottingham.
Upperton Pharma Solutions' new site will be constructed close to its existing base at Nottingham Science Park to enable the company to significantly increase its research and development (R&D) laboratory and manufacturing space.
The new facility, which is scheduled for completion during the fourth quarter of 2023, will see Upperton increase its capacity so it can continue to meet - and expand on - the growing demand for its oral, nasal and pulmonary dosage form development and manufacturing services.
The space will be designed to handle highly potent molecules and controlled drugs, reflecting the increasing number of these molecule types being developed in the industry.
Up to 100 new jobs are expected to be created over the next few years on the back of the investment.
Sign up for your free East Midlands newsletter and follow us on LinkedIn
Email newsletters
BusinessLive is your home for business news from across the East Midlands including Leicestershire, Nottinghamshire, Derbyshire and Lincolnshire.
Click through here to sign up for our email newsletter and also view the broad range of other bulletins we offer including weekly sector-specific updates.
We will also send out 'Breaking News' emails for any stories which must be seen right away.
For all the latest stories, views and polls, follow our
Nikki Whitfield, CEO of Upperton, said: "We are excited to be building new formulation development and analytical laboratories alongside the GMP facility to ensure our operations and capabilities remain state of the art.
"The new facilities will enable us to increase our current development and manufacturing capacity as well as expand our solid dose and spray drying offerings to address the growing needs of our customers."
Most Read
Upperton has more than 20 years experience in delivering science-led early drug development solutions to pharmaceutical and biotechnology clients worldwide.
The company - which employs around 50 staff - uses its expertise to develop a wide-range of non-sterile, finished dosage formats for its clients.
The new facilities will allow Upperton to support existing and new clients further in their product development journey to ensure a "consistent and streamlined pathway to approval".